Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: A systematic review and meta-analysis

International Journal of COPD

Volumn 7, Issue , 2012, Pages 587-595

  Jen, Rachel ^a   Rennard, Stephen I ^b   Sin, Don D ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NEBRASKA MEDICAL CENTER   (United States)

^c ST PAUL S HOSPITAL   (Canada)

Author keywords

Bronchial biopsies; Bronchoalveolar lavage; Chronic obstructive pulmonary disease; Inflammation; Inflammatory markers; Inhaled corticosteroids; Meta analysis

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; GLUCOCORTICOID; ANTIINFECTIVE AGENT;

ADULT; AGED; BRONCHUS BIOPSY; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG LAVAGE; LYMPHOCYTE COUNT; MACROPHAGE; MAJOR CLINICAL STUDY; META ANALYSIS; NEUTROPHIL COUNT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFLAMMATION; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; BIOPSY; DRUG EFFECT; FEMALE; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; LUNG; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; T LYMPHOCYTE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGED; ANTI-INFECTIVE AGENTS; BIOPSY; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84872236803     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S32765     Document Type: Review

References (30)

1. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003;22: 672-688.
2. Cosio MG, Majo J, Cosio MG. Inflammation of the airways and lung parenchyma in COPD: role of T cells. Chest. 2002;121:160S-165S.
3. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55:114-120.
4. Sugiura H, Ichinose M, Yamagata S, Koarai A, Shirato K, Hattori T. Correlation between change in pulmonary function and suppression of reactive nitrogen species production following steroid treatment in COPD. Thorax. 2003;58:299-305.
5. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet. 2009;373:1905-1917.
6. Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary man-agement of chronic obstructive pulmonary disease: scientific review. JAMA. 2003;290:2301-2312.
7. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009;169:219-229.
8. Gan WQ, Man SF, Sin DD. Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm Med. 2005;5:3.
9. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645-2653.
10. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357:1191-1194.
11. Boulet LP, Becker A, Berube D, Beveridge R, Ernst P. Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group. CMAJ. 1999;161:S1-S61.
12. Ozol D, Aysan T, Solak ZA, Mogulkoc N, Veral A, Sebik F. The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients. Respir Med. 2005;99:1494-1500.
13. Reid DW, Wen Y, Johns DP, Williams TJ, Ward C, Walters EH. Bronchodilator reversibility, airway eosinophilia and anti-inflammatory effects of inhaled fluticasone in COPD are not related. Respirology. 2008;13:799-809.
14. Thompson AB, Mueller MB, Heires AJ, et al. Aerosolized beclometha-sone in chronic bronchitis. Improved pulmonary function and dimin-ished airway inflammation. Am Rev Respir Dis. 1992;146:389-395.
15. Verhoeven GT, Garrelds IM, Hoogsteden HC, Zijlstra FJ. Effects of fluticasone propionate inhalation on levels of arachidonic acid metabo-lites in patients with chronic obstructive pulmonary disease. Mediators Inflamm. 2001;10:21-26.
16. Barnes NC, Qiu YS, Pavord ID, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med. 2006;173:736-743.
17. Bourbeau J, Christodoulopoulos P, Maltais F, Yamauchi Y, Olivenstein R, Hamid Q. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax. 2007;62:938-943.
18. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med. 2002;165:1592-1596.
19. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al. Effect of fluti-casone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2009;151:517-527.
20. Gizycki MJ, Hattotuwa KL, Barnes N, Jeffery PK. Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examina-tion of endobronchial biopsy tissue. Thorax. 2002;57:799-803.
21. Verhoeven GT, Wijkhuijs AJ, Hooijkaas H, Hoogsteden HC, Sluiter W. Effect of an inhaled glucocorticoid on reactive oxygen species produc-tion by bronchoalveolar lavage cells from smoking COPD patients. Mediators Inflamm. 2000;9:109-113.
22. O'Donnell R, Breen D, Wilson S, Djukanovic R. Inflammatory cells in the airways in COPD. Thorax. 2006;61:448-454.
23. Hogg JC, Chu FS, Tan WC, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med. 2007;176:454-459.
24. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstruc-tive pulmonary disease. N Engl J Med. 2009;360:2445-2454.
25. Brusselle GG, Demoor T, Bracke KR, Brandsma CA, Timens W. Lymphoid follicles in (very) severe COPD: beneficial or harmful? Eur Respir J. 2009;34:219-230.
26. Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med. 2002;165:1377-1383.
27. Haslett C. Granulocyte apoptosis and its role in the resolution and control of lung inflammation. Am J Respir Crit Care Med. 1999;160:S5-S11.
28. Churg A, Zay K, Shay S, et al. Acute cigarette smoke-induced connec-tive tissue breakdown requires both neutrophils and macrophage metal-loelastase in mice. Am J Respir Cell Mol Biol. 2002;27:368-374.
29. Soriano JB, Sin DD, Zhang X, et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest. 2007;131:682-689.
30. Lapperre TS, Postma DS, Gosman MM, et al. Relation between duration of smoking cessation and bronchial inflammation in COPD. Thorax. 2006;61:115-121.